SOPHiA GENETICS
Cloud platform for decentralized genomic and multimodal health-data analysis.
Something off on this page? Send us feedback.
Profile
Sells pay-per-analysis, cloud-based genomic and multimodal health-data analytics to health care institutions and biopharma organizations, with licensed oncology applications and software products extending the platform. Its decentralized model keeps testing and data at customer institutions while using standardized analysis across the network.
Provides SOPHiA DDM, a cloud-native platform that standardizes, analyzes, and interprets genomic, radiomic, and other multimodal health data for hospitals, laboratories, and biopharma organizations. Clinical-genomics applications address oncology, rare and inherited disorders, while MSK-ACCESS and MSK-IMPACT pair licensed cancer assays with decentralized analytics. Alamut adds contracted variant-analysis software, and biopharma applications support diagnostic development, trials, and companion-diagnostic deployment.
Earns most revenue when clinical customers run paid analyses, with EMEA as its largest region and direct and distributor coverage extending internationally. The decentralized model lets institutions retain their data while common analytics create insights across a standardized network. Diagnostic commercialization depends on local authorization and reimbursement; many products are research use only unless specifically designated, and platform delivery relies on third-party cloud services.
Company facts
Key statistics
Year to date +74.0% · Average volume (30d) 479.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | BTIG | Reiterate | Buy | $8 | $9 |
| Aug 5, 2026 | H.C. Wainwright | Target | $12 | $14 | |
| Jul 20, 2026 | H.C. Wainwright | Reiterate | Buy | $12 | |
| Apr 15, 2026 | BTIG | Reiterate | Buy | $7 | $8 |
| Mar 3, 2026 | BTIG | Target | $5 | $7 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.21 | −$0.26 | −23.8% | $21.7M | $23.3M | +7.3% | +20.21% |
| May 5, 2026Q1 FY26 | −$0.23 | −$0.27 | −16.1% | $20.4M | $21.7M | +6.3% | −0.99% |
| Mar 3, 2026Q4 FY25 | −$0.24 | −$0.28 | −17.9% | $20.5M | $21.7M | +5.9% | +2.93% |
| Nov 4, 2025Q3 FY25 | −$0.20 | −$0.30 | −50.0% | $20.5M | $19.5M | −5.0% | −3.42% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $17.8M | $18.3M | $19.5M | $21.7M | $21.7M | $23.3M | |
| Gross profit | $12.2M | $12.3M | $12.9M | $14.7M | $14.7M | $15.1M | |
| Operating income | −$16.0M | −$18.6M | −$17.9M | −$18.0M | −$17.3M | −$20.1M | |
| Net income | −$17.4M | −$22.4M | −$20.0M | −$19.2M | −$19.3M | −$22.4M | |
| Diluted EPS | −$0.26 | −$0.33 | −$0.30 | −$0.28 | −$0.27 | −$0.30 | |
| Gross margin | 68.7% | 67.0% | 66.3% | 67.7% | 68.0% | 64.6% | |
| Operating margin | -90.2% | -101.3% | -91.8% | -83.1% | -79.7% | -86.0% |
Fiscal years (4-quarter sums)FY21 $40.5M · FY22 $47.6M · FY23 $62.4M · FY24 $65.2M · FY25 $77.3M
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $107.7M · Total debt $61.8M · Total assets $198.4M · Shareholders' equity $83.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 83.90M · Float 72.00M · 85.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Generation Investment Management LLP | 6.79M | 8.09% | 13F | Aug 10, 2026 |
| Aigh Capital Management LLC | 3.95M | 4.71% | 13F | Aug 7, 2026 |
| Akre Capital Management LLC | 3.72M | 4.43% | 13F | Aug 14, 2026 |
| Jurgi Camblong · director, officer: Executive Chairman | 3.44M | 4.11% | Form 4 | Aug 10, 2026 |
| Royce & Associates LP | 3.38M | 4.03% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Kathy L. Hibbs | director | −6,250 | $8.68 |
| Aug 25, 2026 | Philippe Menu | officer: Chief Medical Officer | −5,000 | $8.68 |
| Aug 24, 2026 | Abhimanyu Verma | officer: Chief Technology Officer | −5,000 | $8.80 |
| Aug 19, 2026 | Abhimanyu Verma | officer: Chief Technology Officer | −5,000 | $8.20 |
| Aug 21, 2026 | Zhenyu Xu | officer: Chief Scientific Officer | −5,408 | $8.40 |
Peers
- Tempus AI
Multimodal oncology AI and biopharma data compete at platform scale.
- Illumina
NGS analysis pipelines contest clinical oncology and rare-disease labs.
- QIAGEN
Clinical NGS reporting competes in cancer and rare-disease laboratories.
- Caris Life Sciences
Comprehensive cancer profiling and multimodal AI pursue oncology accounts.
- Thermo Fisher Scientific
Cloud NGS analysis and reporting overlap in clinical laboratory workflows.
- Agilent Technologies
Clinical variant interpretation overlaps in oncology and inherited disease.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SOPHiA GENETICS | $8.10 | −0.31% | $682.9M | — | — | 7.9 | +27.2% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Illumina | $215.70 | +0.02% | $32.62B | 40.2 | 37.6 | 7.3 | +9.4% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Median | 33.5 | 23.8 | 6.6 | +10.0% |